HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

Noopur Raje, MD, on Unmet Needs With CAR T-Cell Therapy in Multiple Myeloma

The director of the Center for Multiple Myeloma and Mass Gen discussed unmet needs with CAR T-cell therapy in multiple myeloma.

This content originally appeared on our sister site, OncLive.

Access remains the most prevalent unmet need regarding CAR T-cell therapy, which is currently approved only for patients with late-stage relapsed or refractory multiple myeloma. Patients must wait and sometimes cannot receive the products in time.

OncLive spoke with Noopur Raje, MD, director, Center for Multiple Myeloma, Massachusets General Hospital, about these unmet needs with CAR T-cell therapy in multiple myeloma. She discussed how improving access for these patients is a vital concern.

Raje discussed the potential of moving CAR T-cell therapy into earlier stages of treatment to help improve access and expand the number of patients who could receive treatment. Ciltacabtagene autoleucel (cilta-cel; Carvykti) and idecabtagene vicleucel (ide-cel; Abecma) are currently being investigated in the up-front setting in clinical trials. Once the indication is received in earlier stages of myeloma, bridging therapies will help more patients receive CAR T-cell therapy, Raje concluded.